Omeros (FRA:3O8) Total Operating Expense : €152.69 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Total Operating Expense?

Omeros's Total Operating Expense for the three months ended in Dec. 2023 was €36.47 Mil. Omeros's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €152.69 Mil.

Omeros Total Operating Expense Historical Data

The historical data trend for Omeros's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Total Operating Expense Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Operating Expense

Get a 7-Day Free Trial

131.43

188.92

153.65

154.24

150.87

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Operating Expense	Get a 7-Day Free Trial															37.89	33.36	37.75	45.12	36.47

Omeros Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €152.69 Mil.

Omeros Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Omeros's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines